Kinoshita M, Kume E, Tamaki H
Department of Pharmacology, Tanabe Seiyaku Co., Ltd., Saitama, Japan.
J Pharmacol Exp Ther. 1995 Oct;275(1):494-501.
We determined the mechanism of the gastroprotective effects of ecabet sodium (ecabet), a new antiulcer drug. Ecabet (12.5-100 mg/kg p.o.) dose-dependently protected gastric mucosa from ethanol-induced injuries in rats, as determined with the use of both macroscopic and microscopic analyses. Both inhibition of prostaglandin (PG) formation by indomethacin (5 mg/kg s.c.) and functional ablation of capsaicin-sensitive sensory nerves (CPSN) by systemic administration of capsaicin (125 mg/kg s.c.) partly reduced the gastroprotective activity of ecabet (25 and 100 mg/kg p.o.). Ecabet increased rat gastric mucosal PGE2 formation. The treatment with indomethacin but not capsaicin decreased the ecabet-induced increase in PGE2 formation. Inhibition of nitric oxide (NO) formation by NG-monomethyl-L-arginine (L-NMMA; 100 mg/kg i.v.) partly reversed the gastroprotective effect of ecabet and completely reversed that of capsaicin at an oral dose of 0.5 mg/kg, respectively. The effect of L-NMMA was abolished by pretreatment with L-arginine (100 mg/kg i.v.) but not with D-arginine (100 mg/kg i.v.). The gastroprotective activity of ecabet (25 mg/kg p.o.) was fully reversed by pretreatment with indomethacin in combination with L-NMMA or CPSN ablation. On the contrary, a combination of L-NMMA and CPSN ablation did not have additional effect on the suppression by either treatment alone. These findings indicate that the gastroprotection by ecabet is cooperatively mediated by endogenous PGs and CPSN-related endogenous NO.
我们确定了新型抗溃疡药物依卡倍特钠(依卡倍特)的胃保护作用机制。通过宏观和微观分析确定,依卡倍特(12.5 - 100毫克/千克,口服)能剂量依赖性地保护大鼠胃黏膜免受乙醇诱导的损伤。吲哚美辛(5毫克/千克,皮下注射)抑制前列腺素(PG)形成以及辣椒素(125毫克/千克,皮下注射)全身给药功能性消除辣椒素敏感感觉神经(CPSN),均部分降低了依卡倍特(25和100毫克/千克,口服)的胃保护活性。依卡倍特增加大鼠胃黏膜PGE2的形成。吲哚美辛而非辣椒素处理降低了依卡倍特诱导的PGE2形成增加。NG - 单甲基 - L - 精氨酸(L - NMMA;100毫克/千克,静脉注射)抑制一氧化氮(NO)形成,分别部分逆转了依卡倍特的胃保护作用,并完全逆转了口服剂量为0.5毫克/千克辣椒素的胃保护作用。L - 精氨酸(100毫克/千克,静脉注射)预处理可消除L - NMMA的作用,但D - 精氨酸(100毫克/千克,静脉注射)预处理则不能。吲哚美辛联合L - NMMA预处理或CPSN消除可完全逆转依卡倍特(25毫克/千克,口服)的胃保护活性。相反,L - NMMA和CPSN消除联合使用对单独使用任何一种处理的抑制作用没有额外影响。这些发现表明,依卡倍特的胃保护作用是由内源性PGs和CPSN相关的内源性NO协同介导的。